
Opinion|Videos|July 15, 2024
Oral JAK Inhibitors in Atopic Dermatitis
Author(s)Ruth Ann Vleugels, MD, MPH, MBA
Ruth Ann Vleugels, MD, MPH, MBA, provides an overview of oral JAK inhibitors approved for the treatment of atopic dermatitis and describes what makes them an attractive therapeutic option.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following questions:
- Please review the oral JAK inhibitors that have been approved for atopic dermatitis (AD).
- Which patients are they approved for?
- What makes JAK inhibitors an attractive option for AD treatment?
- How are oral JAK inhibitors utilized in other diseases?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
4
When and How to Escalate Pediatric Atopic Dermatitis Treatment
5
























































